FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating Huntington's disease, a…
Central Nervous System
-
-
FDA approves Neurelis’ nasal spray for seizures
The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute…
-
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease.…
-
Cingulate secures $3m to advance once-daily anxiety treatment
US biopharmaceutical company Cingulate has announced the receipt of a $3m grant from a private foundation to expedite the development…
-
ABL Bio and GSK link on neurodegenerative conditions
ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative conditions. Through…
-
Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
Neurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for…
-
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s
At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of digital health technologies (DHTs)…
-
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
-
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate…
-
Tempero secures $70m to advance addiction treatment candidate
Tempero Bio has raised $70m in Series B financing to advance its lead candidate TMP-301 through two clinical trials for…
